HEMATOPOIETIC GROWTH-FACTORS AND DOSE INTENSITY IN HIGH-GRADE AND INTERMEDIATE-GRADE LYMPHOMA

被引：10

作者：

PETTENGELL, R

CROWTHER, D

机构：

来源：

ANNALS OF ONCOLOGY | 1994年 / 5卷

关键词：

DOSE INTENSITY; HEMATOPOIETIC GROWTH FACTORS; NON-HODGKINS LYMPHOMA;

D O I：

10.1093/annonc/5.suppl_2.S134

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Here we review the evidence that cytotoxic dose intensity is an important determinant of outcome in high- and intermediate-grade non-Hodgkin's lymphoma. The results of retrospective analyses and prospective studies support this proposition but confirmatory studies are required. We discuss the role of haemopoietic growth factors and mobilized peripheral blood progenitor cells to increase dose intensity. Studies using these modalities will enable the importance of dose intensity to be tested.

引用

页码：S133 / S141

页数：9

共 70 条

[1] GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) AS AN ADJUNCT TO AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION FOR LYMPHOMA [J].

ADVANI, R ;

CHAO, NJ ;

HORNING, SJ ;

BLUME, KG ;

AHN, DK ;

LAMBORN, KR ;

FLEMING, NC ;

BONNEM, EM ;

GREENBERG, PL .

ANNALS OF INTERNAL MEDICINE, 1992, 116 (03) :183-189

[2] CHEMOTHERAPY FOR DIFFUSE LARGE-CELL LYMPHOMA - RAPIDLY RESPONDING PATIENTS HAVE MORE DURABLE REMISSIONS [J].

ARMITAGE, JO ;

WEISENBURGER, DD ;

HUTCHINS, M ;

MORAVEC, DF ;

DOWLING, M ;

SORENSEN, S ;

MAILLIARD, J ;

OKERBLOOM, J ;

JOHNSON, PS ;

HOWE, D ;

BASCOM, GK ;

CASEY, J ;

LINDER, J ;

PURTILO, DT .

JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (02) :160-164

[3]

BAER MR, 1986, CANCER TREAT REP, V70, P785

[4]

BLAYNEY DW, 1992, P AN M AM SOC CLIN, V11, P320

[5] BONE-MARROW TRANSPLANTATION PROLONGS SURVIVAL AFTER RELAPSE IN AGGRESSIVE-LYMPHOMA PATIENTS TREATED WITH THE LNH-84 REGIMEN [J].

BOSLY, A ;

COIFFIER, B ;

GISSELBRECHT, C ;

TILLY, H ;

AUZANNEAU, G ;

ANDRIEN, F ;

HERBRECHT, R ;

LEGROS, M ;

DEVAUX, Y ;

JAUBERT, J ;

PIGNON, B ;

MICHAUX, JL ;

HUMBLET, Y ;

DUPRIEZ, B ;

THYSS, A ;

LEDERLIN, P ;

MARTIN, C ;

DAVID, B ;

MARRIT, G ;

FERME, C ;

SALLES, B ;

BLANC, M ;

DUPONT, G ;

TERTIAN, G ;

BIGNON, JY ;

PLAGNE, R ;

LEGROS, M ;

TRAVADE, P ;

SOLALCELIGNY, P ;

ZYLBERAIT, D ;

CHAUFFERT, B ;

CAILLOT, D ;

GUY, H ;

BAUTERS, F ;

DUPRIEZ, B ;

FENAUX, P ;

JOUET, JP ;

DEVAUX, Y ;

FFRENCH, M ;

FIERE, D ;

SEBBAN, C ;

VIALA, JJ ;

CORDIER, JF ;

TRILLET, V ;

LEDERLIN, P ;

SCHNEIDER, M ;

THYSS, A ;

BERNADOU, A ;

AUZANNEAU, G ;

BOIRON, M .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (10) :1615-1623

[6]

BRUCE WR, 1966, JNCI-J NATL CANCER I, V37, P233

[7]

BRUGGER W, 1992, BLOOD, V79, P1193

[8] LNH-84 REGIMEN - A MULTICENTER STUDY OF INTENSIVE CHEMOTHERAPY IN 737 PATIENTS WITH AGGRESSIVE MALIGNANT-LYMPHOMA [J].

COIFFIER, B ;

GISSELBRECHT, C ;

HERBRECHT, R ;

TILLY, H ;

BOSLY, A ;

BROUSSE, N .

JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (08) :1018-1026

[9] THE ROLE OF AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN 46 ADULT PATIENTS WITH NON-HODGKINS-LYMPHOMAS [J].

COLOMBAT, P ;

GORIN, NC ;

LEMONNIER, MP ;

BINET, C ;

LAPORTE, JP ;

DOUAY, L ;

DESBOIS, I ;

LOPEZ, M ;

LAMAGNERE, JP ;

NAJMAN, A .

JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (04) :630-637

[10]

Coltman CA, 1986, ADV CHEMOTHERAPY UPD, P71

← 1 2 3 4 5 6 7 →